<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131897</url>
  </required_header>
  <id_info>
    <org_study_id>AA06179</org_study_id>
    <nct_id>NCT01131897</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Levetiracetam Tablets, 750 mg and Keppra® 750 mg Tablets of UCB Pharma in Healthy Adult Male Volunteers Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the single-dose relative bioavailability study of
      Levetiracetam Tablets 750 mg with Keppra® 750 mg Tablets under Fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, single-dose 2-way crossover relative bioavailability study
      in healthy adult male volunteers under fasting conditions with a washout period of 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Keppra®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Keppra® 750 mg Tablets of UCB Pharma Inc.,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_label>Keppra®</arm_group_label>
    <other_name>Keppra® 750 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male volunteers, 18 to 55 years of age;

          -  Weighing at least 60 kg and within 15% of their ideal weights (Table of &quot;Desirable
             Wights of Adults&quot;, Metropolitan Life Insurance Company, 1983);

          -  Medically healthy subjects with clinically normal laboratory profiles and ECGs as
             deemed by the principal investigator;

          -  Voluntarily consent to participate in the study

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  In addition, history or presence of:

               1. alcoholism or drug abuse within the past 2 years;

               2. hypersensitivity or idiosyncratic reaction to levetiracetam;

          -  Subjects who have been on an special diet (for whatever reason) during the 30 days
             prior to the first dose and throughout the study.

          -  Subjects who have made a donation (Standard donation amount or more) of blood or blood
             products (with the exception of plasma as noted below) within 56 days prior to the
             first dose.

          -  Subjects who have made a plasma donation within 7 days prior to the first dose.

          -  Subjects who have participated in another clinical trial within 30 days prior to the
             first dose.

          -  Subjects with hemoglobin less than 12.0 g/dL.

          -  Subjects who have participated in another clinical trial within 30 days prior to the
             first dose.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy L Shenouda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. M.S. Mohan / Senior Manager - R&amp;D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Crossover</keyword>
  <keyword>Levetiracetam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

